SEARCH

SEARCH BY CITATION

References

  • 1
    Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495504.
  • 2
    Magalhaes RL, Braun WE, Straffon RA et al. Microangiopathic hemolytic anemia in renal allotransplantation. Report of a successfully treated case and review of the literature. Am J Med 1975; 58: 862868.
  • 3
    Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55: 24572466.
  • 4
    Mor E, Lustig S, Tovar A et al. Thrombotic microangiopathy early after kidney transplantation: Hemolytic uremic syndrome or vascular rejection? Transplant Proc 2000; 32: 686687.
  • 5
    Waiser J, Budde K, Rudolph B, Ortner MA, Neumayer HH. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am J Kidney Dis 1999; 34: 556559.
  • 6
    Pichette V, Querin S, Schurch W, Brun G, Lehner-Netsch G, Delage JM. Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994; 24: 936941.
  • 7
    Rougier N, Kazatchkine MD, Rougier JP et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. J Am Soc Nephrol 1998; 9: 23182326.
  • 8
    Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J et al. Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41: e84.
  • 9
    Richards A, Kemp EJ, Liszewski MK et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 2003; 100: 1296612971.
  • 10
    Geraghty MT, Perlman EJ, Martin LS et al. Cobalamin C defect associated with hemolytic-uremic syndrome. J Pediatr 1992; 120: 934937.
  • 11
    Kind T, Levy J, Lee M, Kaicker S, Nicholson JF, Kane SA. Cobalamin C disease presenting as hemolytic-uremic syndrome in the neonatal period. J Pediatr Hematol Oncol 2002; 24: 327329.
  • 12
    Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: A severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710713.
  • 13
    Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 15781584.
  • 14
    Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 15851594.
  • 15
    Schneppenheim R, Budde U, Oyen F et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003; 101: 18451850.
  • 16
    Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 30973103.
  • 17
    Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 2001; 47: 387392.
  • 18
    Scheiflinger F, Knobl P, Trattner B et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003; 102: 32413243.
  • 19
    Gungor T, Furlan M, Lammle B, Kuhn F, Seger RA. Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40: 940942.
  • 20
    Furlan M, Robles R, Solenthaler M, Lammle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 28392846.
  • 21
    Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, Mannucci PM. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004; 127: 433439.
  • 22
    Miyata T, Kokame K, Banno F. Measurement of ADAMTS13 activity and inhibitors. Curr Opin Hematol 2005; 12: 384389.
  • 23
    Rieger M, Mannucci PM, Kremer Hovinga JA et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 12621267.
  • 24
    Studt JD, Hovinga JA, Antoine G et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: In vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 542544.
  • 25
    Pham PT, Danovitch GM, Wilkinson AH et al. Inhibitors of ADAMTS13: A potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation 2002; 74: 10771080.
  • 26
    Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 2001; 98: 17651772.
  • 27
    Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 1983; 80: 37343737.
  • 28
    Heurkens AH, Hiemstra PS, Lafeber GJ, Daha MR, Breedveld FC. Anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by vasculitis. Clin Exp Immunol 1989; 78: 712.
  • 29
    Fremeaux-Bacchi V, Moulton EA, Kavanagh D et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17: 20172025.
  • 30
    Furlan M, Lammle B. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Baillieres Clin Haematol 1998; 11: 509514.
  • 31
    Soejima K, Nakagaki T. Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies. Semin Hematol 2005; 42: 5662.
  • 32
    Hamilton DV, Calne RY, Evans DB. Hemolytic-uraemic syndrome and cyclosporin A. Lancet 1982; 2: 151152.
  • 33
    Abraham KA, Little MA, Dorman AM, Walshe JJ. Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 2000; 13: 443447.
  • 34
    Chen W, Thoburn CJ, Miura Y et al. Autoimmune-mediated vasculopathy. Clin Immunol 2001; 100: 5770.
  • 35
    Shang D, Zheng XW, Niiya M, Zheng XL. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006; 108: 22072215.
  • 36
    Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005; 105: 10851093.
  • 37
    Ono T, Mimuro J, Madoiwa S et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood 2006; 107: 528534.